Omololu Falobi Awards for Excellence in HIV Prevention Research Community Advocacy presented

February 25, 2008

24 February, New Delhi, India -- Two advocates have received the inaugural Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy. The awards honor the late Omololu Falobi, a long-time HIV advocate and journalist who founded Journalists Against AIDS in Nigeria, was an instrumental pioneer member of the Nigerian Treatment Access Movement, and co-founded the Nigerian HIV Vaccine & Microbicide Advocacy Group. Omololu was killed in Lagos, Nigeria in October 2006.

The award was created to celebrate the life and values of this remarkable man and to create an ongoing legacy that recognizes his commitment and lasting contributions to HIV prevention research advocacy. The award will highlight the essential role of community advocacy and leadership in HIV prevention research.

"Omololu was a visionary leader and activist, who accomplished much in his short life. He dedicated himself to powerful advocacy around HIV and HIV prevention research in Nigeria, Africa and worldwide. He set new standards for HIV journalism on the continent and facilitated dialogue and engagement between communities, researchers, policy makers, media and civil society around vaccines and microbicides," said Mitchell Warren of AIDS Vaccine Advocacy Coalition. "This award will honor advocates around the world who share Omololu's vision."

Impressed with the calibre of the individuals nominated, the independent review committee have selected two individuals to receive the inaugural Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy award -- Srikrishnan Aylur Kailasam for community advocacy, and Lori Heise for international leadership. This is a mirror to Omololu's own work and vision -- community focus with international scope.

Srikrishnan Aylur Kailasam is the Research Manager at the Y.R. Gaitonde Center for AIDS Research and Education in Chennai, India. Kailasam was honored for his pivotal role in working with and supporting marginalized communities in research settings. In selecting Kailasam for this Award, the selection committee noted his leadership in community research in India, and his commitment to, and respect for the communities that he works with. This has enabled those communities to be not only more informed about research and the importance of research, but also benefit from that research. Kailasam has worked tirelessly to develop bridges between science and community, and strives to improve the quality of life of the communities he serves.

Lori Heise is the Director for the Global Campaign for Microbicides, based in Washington D.C. Heise was honored for her leadership and commitment to the involvement of communities in microbicide research as partners, and her visionary leadership as a founding member of the Global Campaign for Microbicides. The selection committee praised Heise's practice in cultivating leadership and inspiring advocates worldwide. It is with this mandate, that she has led the Campaign to use its resources to build capacity, support leadership, and implement joint projects with other NGOs, many of them now vital leaders. The committee highlighted one referee's words in saying, "the field of microbicide advocacy is the lengthened shadow of one woman, Lori Heise"

The honorees were chosen by an independent international panel of HIV prevention research advocates and researchers, including Salim Abdool Karim of South Africa, Nomita Chandhiok of India, Tim Farley of Switzerland, Nadine France of Thailand, Shaun Mellors of the South Africa, Alex Menezes of Brazil, Kingsley Obom-Egbulem of Nigeria, Badri Saxena of India, and Laurie Sylla of USA. The award review committee was constituted and invited to play this role by the Award Planning Committee.

The inaugural Falobi awards will be presented at the Closing Ceremony of International Microbicides 2008 Conference in New Delhi, India. The planning committee has raised resources to ensure that the award is sustained through the next decade.

"This award is important in keeping Omololu's vision alive. It will be a visible platform for ongoing recognition of the contribution of advocates and leaders to the HIV prevention research field," said Olayide Akanni of Journalists Against AIDS in Nigeria. "We are pleased to launch the award by honouring two people who have made enormous contributions to the field. Omololu would be proud of their work and deserving of this honour."
The award was conceptualised and the process coordinated by the African Microbicides Advocacy Group (AMAG) in partnership with the AIDS Vaccine Advocacy Coalition (AVAC), the Global Campaign for Microbicides (GCM), Journalists Against AIDS in Nigeria (JAAIDS), the Nigerian HIV Vaccine & Microbicides Advocacy Group (NHVMAG), and the Treatment Action Movement Nigeria (TAM). Financial support for the 2008 Award came from AMAG, AVAC, GCM, NHVMAG and Family Health International.

AIDS Vaccine Advocacy Coalition (AVAC)

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to